EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

AKR1C3 in carcinomas: from multifaceted roles to therapeutic strategies

Mengnan Li, Limin Zhang, Jiahui Yu, Xiaoxiao Wang, Le Cheng, Zhaowu Ma, Xiaoguang Chen, Lingzhi Wang, Boon Cher Goh

Frontiers in Pharmacology · 08.03.2024 · 15

DOI: 10.3389/fphar.2024.1378292 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Frontiers in Pharmacology, online erschienen am 08.03.2024. Verfasst von Mengnan Li und 8 weiteren Autor:innen. Beteiligte Einrichtung: School of Basic Medicine, Health Science Center, Yangtze University, Jingzhou, China. Die Arbeit wurde bisher 34-mal zitiert (Crossref) und nennt 120 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aldo-Keto Reductase Family 1 Member C3 (AKR1C3), also known as type 5 17β-hydroxysteroid dehydrogenase (17β-HSD5) or prostaglandin F (PGF) synthase, functions as a pivotal enzyme in androgen biosynthesis. It catalyzes the conversion of weak androgens, estrone (a weak estrogen), and PGD2 into potent androgens (testosterone and 5α-dihydrotestosterone), 17β-estradiol (a potent estrogen), and 11β-PGF2α, respectively. Elevated levels of AKR1C3 activate androgen receptor (AR) signaling pathway, contributing to tumor recurrence and imparting resistance to cancer therapies. The overexpression of AKR1C3 serves as an oncogenic factor, promoting carcinoma cell proliferation, invasion, and metastasis, and is correlated with unfavorable prognosis and overall survival in carcinoma patients. Inhibiting AKR1C3 has demonstrated potent efficacy in suppressing tumor progression and overcoming treatment resistance. As a result, the development and design of AKR1C3 inhibitors have garnered increasing interest among researchers, with significant progress witnessed in recent years. Novel AKR1C3 inhibitors, including natural products and analogues of existing drugs designed based on their structures and frameworks, continue to be discovered and developed in laboratories worldwide. The AKR1C3 enzyme has emerged as a key player in carcinoma progression and therapeutic resistance, posing challenges in cancer treatment. This review aims to provide a comprehensive analysis of AKR1C3’s role in carcinoma development, its implications in therapeutic resistance, and recent advancements in the development of AKR1C3 inhibitors for tumor therapies.

Schlagwörter

Stichwörter der Autor:innen

AKR1C3carcinoma progressioncombination therapiesinhibitorstherapeutic resistance

Autor:innen und Institutionen

  • School of Basic Medicine, Health Science Center, Yangtze University, Jingzhou, China.
  • Jingzhou Hospital of Traditional Chinese Medicine, Jingzhou, China.
  • The Third Clinical Medical College of Yangtze University, Jingzhou, China.
  • Department of Haematology-Oncology, National University Cancer Institute, Singapore, Singapore.
  • NUS Center for Cancer Research (N2CR), Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.
  • Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.

Zitieren

APA

Li, M., Zhang, L., Yu, J., Wang, X., Cheng, L., Ma, Z., Chen, X., Wang, L., & Goh, B. C. (2024). AKR1C3 in carcinomas: from multifaceted roles to therapeutic strategies. Frontiers in Pharmacology, 15. https://doi.org/10.3389/fphar.2024.1378292

Vancouver

Li M, Zhang L, Yu J, Wang X, Cheng L, Ma Z, et al. AKR1C3 in carcinomas: from multifaceted roles to therapeutic strategies. Frontiers in Pharmacology. 2024;15. doi:10.3389/fphar.2024.1378292

BibTeX
@article{Li2024,
  author = {Li, Mengnan and Zhang, Limin and Yu, Jiahui and Wang, Xiaoxiao and Cheng, Le and Ma, Zhaowu and Chen, Xiaoguang and Wang, Lingzhi and Goh, Boon Cher},
  title = {AKR1C3 in carcinomas: from multifaceted roles to therapeutic strategies},
  journal = {Frontiers in Pharmacology},
  year = {2024},
  volume = {15},
  doi = {10.3389/fphar.2024.1378292}
}
Kostenlos starten →